Lv, Fang

Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC

Gao, S., Li, N., Gao, S., Xue, Q., Ying, J., Wang, S., Tao, X., Zhao, J., Mao, Y., Wang, B., et al. (2020) · Journal of Thoracic Oncology

Cancer Immunotherapy and BiomarkersLung Cancer Diagnosis and Treatment

Cited by 401

Characterizing body composition modifying effects of a glucagon-like peptide 1 receptor-based agonist: A meta-analysis

Jiao, R., Lin, C., Cai, X., Wang, J., Wang, Y., Lv, F., Yang, W., & Ji, L. (2025) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementPharmacology and Obesity Treatment

Cited by 60

A comparison of daily glucose fluctuation between GCK-MODY and type 2 diabetes using continuous glucose monitoring technology

Ren, Q., Zhang, P., Pang, W., Ma, Y., Gong, S., Ba, T., Liu, W., Zhang, F., Zhang, X., Zhang, R., et al. (2023) · Diabetes

Diabetes Management and ResearchPancreatic function and diabetes

Cited by 14